Novo may gain more than expected from Medicare obesity drug Bridge program

STAT reports that Novo Nordisk may be receiving a more favorable deal than anticipated under Medicare's Bridge pilot program, which covers obesity drugs for seniors at $245/month. The program, initiated under the Trump administration, benefits both Novo and Eli Lilly, but the analysis suggests Novo's terms are better than expected. This matters as it could affect competitive dynamics in the obesity drug market and Medicare's fiscal exposure.